Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.32 |
| ▸ | SMO | Q99835 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 3/20 | 0.32 |
| ▸ | JAK1 | P23458 | 3/20 | 0.32 |
| ▸ | TYK2 | P29597 | 3/20 | 0.32 |
| ▸ | JAK3 | P52333 | 3/20 | 0.32 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.30 |
| ▸ | AURKA | O14965 | 2/20 | 0.30 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1702206 | 0.90 | CYP3A4 (0.40) | CYP3A4PDCD1CD274SMOJAK2 | |
| SCHEMBL16508298 | 0.84 | JAK2 (0.34) | CYP3A4SMOJAK2JAK1TYK2 | |
| SCHEMBL2448559 | 0.75 | CYP3A4 (0.41) | CYP3A4SMOJAK2JAK1TYK2 | |
| SCHEMBL3796409 | 0.72 | CYP3A4 (0.40) | CYP3A4SMOJAK2JAK1TYK2 | |
| SCHEMBL2448864 | 0.72 | CYP3A4 (0.40) | CYP3A4SMOJAK2JAK1TYK2 | |
| SCHEMBL16508295 | 0.67 | CYP3A4 (0.49) | CYP3A4 | |
| SCHEMBL16508297 | 0.65 | CYP3A4 (0.35) | CYP3A4JAK2JAK3IRAK1AURKA | |
| SCHEMBL1702705 | 0.65 | CYP3A4 (0.38) | CYP3A4 | |
| SCHEMBL2450989 | 0.65 | CYP3A4 (0.41) | CYP3A4 | |
| SCHEMBL16508263 | 0.64 | SGK1 (0.39) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110300103-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC (US) | 2011-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110300103-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, IRF3 | CYP3A4 55/4885PDCD1 2271/4885CD274 2422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.